When is NEPH's next earnings date?

Based on SEC filing cadence, Nephros Inc. (NEPH)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is NEPH stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for NEPH, spanning a range between $2.77 and $3.57.

Stock Ratings / Health Care / NEPH / earnings

TELA (35) CVRX (31) BEAT (42) XTNT (65) ⌘ Pro Terminal →

Nephros Inc. (NEPH) Next Earnings Date & Expected ±12.5% Move

$3.17 -3.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.15

Nephros Inc. (NEPH) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $34.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NEPH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Nephros Inc. (NASDAQ: NEPH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.17 (-3.06% 1D, market cap $34.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, NEPH ranks #175 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NEPH compare to TELA and CVRX in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), NEPH carries a Roarable C- (59/100 RQD), trailing P/E of 29.8x, gross margin of 61.9%, and ROIC of 18.9%. By comparison, TELA (TELA Bio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $36.6M) and CVRX (CVRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NEPH?

▼

Per NEPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001196298), Nephros Inc. generated $18.8M in revenue (+32.7% YoY), $1.2M in net income, and $1.6M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (61.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.15 (-0.74%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 8.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEPH)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY NEPH SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 8.5% FCF Margin ($1.6M FCF) & 61.9% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$3.59-1.9% Next Q

Q2 (-2Q)

Grade C+$3.52-0.3% Next Q

Q3 (-1Q)

Grade C+$3.51-9.7% Next Q

Current

Grade C-$3.17+0.2% Hist 90D α

Trajectory: B- (67) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NEPH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, NEPH faces multiple-compression risk if 29.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.86) or 200D SMA ($3.66) invalidates the momentum regime and cuts Target Base ($3.18) toward Bear Floor ($2.48).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NEPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.40 Expected Swing

MODEL EARNINGS SETUP GAUGE

NEPH Quantitative Pre-Earnings Setup: 59/100

Trailing EPS: $0.11 • YoY Revenue Growth: 32.7%

Model Bullish Setup (59/100)Model Risk Weight (41/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$18.8M	$1.2M	$1.6M	61.9%
FY 2024	2024-12-31	$14.2M	$74.0K	-$547.0K	61.6%
FY 2023	2023-12-31	$14.2M	-$1.6M	$827.0K	61.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating NEPH & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on NEPH
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.26%🛡️ HOLDING TREND SUPPORT

2026-11-03O $3.27H $3.27L $3.17C $3.17VOL 12.4K

RES: $5.70SUP: $2.99SMA50: $3.86SMA200: $3.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEPH Butterfly Map → + Track NEPH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

23.0%/yr Implied 5Y Growth

vs. +32.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NEPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEPH)

Health Care Rank #175 of 1015 ⚔️ TELA vs NEPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEPH vs. TELA, CVRX, BEAT, XTNT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nephros Inc. (NEPH) ranks #175 by composite RQD confidence (59/100, grade C-) and #783 by equity capitalization ($34.5M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with NEPH at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEPH ACTIVE Nephros Inc.	C-	59/100	29.8x	61.9%	18.9%	-3.06%	$34.5M	Benchmark Subject
TELA TELA Bio Inc.	D-	35/100	—	67.7%	-35.0%	-11.95%	$36.6M	/tela-vs-neph →
CVRX CVRx Inc.	E	31/100	—	85.3%	-35.0%	-1.05%	$37.6M	/cvrx-vs-neph →
BEAT Heartbeam Inc.	D-	42/100	—	—	-35.0%	+2.06%	$31.0M	/beat-vs-neph →
XTNT Xtant Medical Holdings Inc.	C	65/100	—	62.9%	12.8%	-3.51%	$39.3M	/xtnt-vs-neph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001196298 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nephros Inc. (NEPH) reported GAAP revenue of $18.8M (+32.7% vs. FY2024 revenue of $14.2M , and +32.0% cumulative change since FY2023) , GAAP net income of $1.2M, operating cash flow of $1.6M, and free cash flow of $1.6M (+392.5% YoY). On the balance sheet, NEPH closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$18.8M	$1.2M	$1.6M	$1.6M	$13.6M	—
FY2024 (FY)	2024-12-31	$14.2M	$74.0K	-$492.0K	-$547.0K	$11.2M	—
FY2023 (FY)	2023-12-31	$14.2M	-$1.6M	$827.0K	$827.0K	—	—

3. NEPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NEPH compare to TELA and CVRX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NEPH?

Where is NEPH trading relative to its 50-day, 200-day, and 52-week technical levels?

NEPH last traded at $3.17 (-3.06% on volume of 12,421 shares), positioning the stock -17.88% below its 50-day simple moving average ($3.86) and -13.39% below its 200-day simple moving average ($3.66). Across its 52-week range of $2.66 to $6.42, NEPH sits at the 13.6% percentile with a 14-day RSI of 38.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.77 to $3.57).

Direct Sub-Reports: NEPH RQD Cockpit NEPH 12M Forecast NEPH Earnings & Move NEPH Dividends & DRIP NEPH Insiders & 13F NEPH Whale Options NEPH Profit Sankey NEPH News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

NEPH — Nephros Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nephros Inc. (NEPH) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $3.17 (-3.06% 1D, market capitalization $34.5M).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 18.9%, gross margin of 61.9%, operating margin of 6.1%, and free cash flow yield of 4.50%.
Whale 13F & Options Flow (3/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (15/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the market data, gross margin is 61.9%, indicating meaningful pricing power or product mix advantage.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nephros Inc. (NEPH) reported $18.8M in annual revenue (up from $14.2M in FY2024, +32.7% YoY) and $1.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($14.2M revenue, -$1.6M net income) through FY2025, NEPH scaled operating cash flow to $1.6M and free cash flow to $1.6M, backed by $13.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C- • RQD 59/100): Strong cash generator (61.9% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.66 – $6.42 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 29.8x trailing P/E and 26.3x EV/EBITDA against 6.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), NEPH carries a macro regime beta of 1.00 and gross margin of 61.9%.

Key Question #1: Can NEPH sustain or expand its 6.1% operating margin and 18.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $18.8M and free cash flow of $1.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NEPH's 25.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NEPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nephros Inc. (NEPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NEPH Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 23h ago

Nephros, Inc. Estimates – NASDAQ:NEPH

TradingView report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Nephros, Inc. (NEPH) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Nephros Inc. (NEPH) Edges Lower to $3.52 as Shares Sit Midway Between Key Support and Resistance - Late Stage Breakouts

https://www.siam.in/ report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Davion Healthcare Plc (DAVI) Stock Price, News & Analysis

Stock Titan report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Nephron Pharmaceuticals’ CEO is out. Here’s past coverage of the company.

Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Lou Kennedy is no longer Nephron Pharmaceuticals CEO

Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Nephron's Lou Kennedy out as CEO in 'leadership transition’. What we know.

Yahoo Finance report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Nephros, Inc. (NEPH) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Nephros Inc. (NEPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NEPH Bull vs. Bear Conversation Board — What's Your Call at $3.17?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEPH 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.80 (+19.9%)

📌 Pinned Debate

Revenue grew from $14.2M to $18.8M while ROIC of 18.9% and a Piotroski F-Score of 8/9 signal improving cash generation and balance shee

Long NEPH at $3.17 targeting $3.80. Revenue grew from $14.2M to $18.8M while ROIC of 18.9% and a Piotroski F-Score of 8/9 signal improving cash generation and balance sheet quality.. Institutional whale score is 3/20 and the risk/reward vs. the $2.66 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — NEPH's 15/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $2.60 (-18.0%)

Spot @ $3.17

Valuation remains elevated at 29.8x TTM P/E and 26.3x EV/EBITDA against a 6.1% operating margin, with institutional whale flow scoring

Sitting on the sidelines or leaning short NEPH above $3.17. Valuation remains elevated at 29.8x TTM P/E and 26.3x EV/EBITDA against a 6.1% operating margin, with institutional whale flow scoring only 3/20.. Until Fundamental Cash Engine (16/20) and FCF yield (4.5%) inflect higher, upside is capped near $6.42.